Highlights from the 3rd Annual CCA Summit

Dr Timothy Yap comments on the challenges in using ctDNA in detecting FGFR fusions and the potential of ctRNA in detecting molecular alterations that can drive therapy and monitor both response and resistance to therapy.

Dr Jesus Bañales discusses advances in our understanding of molecular targets that can be used to direct therapy against novel molecular pathways in CCA.

Dr V. Sahai discusses how to move forward with immune-oncology approaches in biliary tract cancers, including key investigations that are needed to improve outcomes with immunotherapy in CCA.

Dr Lewis Roberts discusses molecular biomarkers that may correlate with known epidemiological risk factors associated with the incidence of cholangiocarcinoma, and the types of preclinical and clinical studies that are needed to explore these correlations.

Drs Juan Valle and Angela Lamarca discuss clinical studies being conducted to improve the use of chemotherapy in CCA by exploring molecular biomarkers that could help patient selection for optimal response to certain chemotherapy regimens.